Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease

Journal of the American Society of Nephrology

Volumn 25, Issue 10, 2014, Pages 2231-2240

  Huang, Louis L ^a   Nikolic Paterson, David J ^a   Han, Yingjie ^a   Ozols, Elyce ^a   Ma, Frank Y ^a   Young, Morag J ^b   Tesch, Greg H ^a  

^a MONASH UNIVERSITY   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD11B ANTIGEN; CD163 ANTIGEN; COL1A1 PROTEIN; CYSTATIN C; EPLERENONE; FN1 PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MACROPHAGE ELASTASE; MACROPHAGE MIGRATION INHIBITION FACTOR; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PAI 1 PROTEIN; POTASSIUM; PROTEIN; SODIUM; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GLOMERULUS BASEMENT MEMBRANE; HISTOLOGY; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY INJURY; LEUKOCYTE; MACROPHAGE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PHENOTYPE; PODOCYTE; POLYMERASE CHAIN REACTION; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SODIUM URINE LEVEL; URINARY EXCRETION; WILD TYPE; ANIMAL; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; C57BL MOUSE; DISEASE MODEL; ELECTROLYTE BALANCE; LEUKOCYTE COUNT; METABOLISM;

ANIMALS; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; DISEASE MODELS, ANIMAL; FEMALE; LEUKOCYTE COUNT; MICE, INBRED C57BL; MYELOID CELLS; PODOCYTES; RECEPTORS, MINERALOCORTICOID; WATER-ELECTROLYTE BALANCE;

EID: 84921795795     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012111094     Document Type: Article

References (28)

1. Shibata H, Itoh H: Mineralocorticoid receptor-associated hypertension and its organ damage: Clinical relevance for resistant hypertension. Am J Hypertens 25: 514-523, 2012
2. Zitt E, Eller K, Huber JM, Kirsch AH, Tagwerker A, Mayer G, Rosenkranz AR: The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis. Int J Clin Exp Pathol 4: 606-615, 2011
3. Qin D, Morita H, Inui K, Tayama H, Inoue Y, Yoshimura A: Aldosterone mediates glomerular inflammation in experimental mesangial proliferative glomerulonephritis. J Nephrol 26: 199-206, 2012.
4. Lian M, Hewitson TD, Wigg B, Samuel CS, Chow F, Becker GJ: Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease. Nephrol Dial Transplant 27: 906-912, 2012
5. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, Han KH, Kim HK, Kang YS, Han JY, Kim YS, Cha DR: Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 17: 1362-1372, 2006
6. Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, Kikuchi T, Lapointe N, Pojoga L, Williams GH, Ricchiuti V, Adler GK: Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 147: 5363-5373, 2006
7. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving H-H: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care 28: 2106-2112, 2005
8. van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F: Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 24: 2285-2292, 2006
9. Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, Kamper AL: Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized crossover study. PLoS ONE 6: e26904, 2011
10. Fuller PJ, Young MJ: Mechanisms of mineralocorticoid action. Hypertension 46: 1227-1235, 2005
11. Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, Kishida M, Hamada M, Nagai Y, Nakagawa T, Ohashi N, Nakano D, Hitomi H, Imanishi M: Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther 332: 1072-1080, 2010
12. Lee SH, Yoo TH, Nam BY, Kim DK, Li JJ, Jung DS, Kwak SJ, Ryu DR, Han SH, Lee JE, Moon SJ, Han DS, Kang SW: Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol 297: F1381-F1390, 2009
13. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M: Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: A possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109: 2213-2220, 2004
14. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ: Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54: 537-543, 2009
15. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schütz G, Lumeng CN, Mortensen RM: Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120: 3350-3364, 2010
16. Frieler RA, Meng H, Duan SZ, Berger S, Schütz G, He Y, Xi G, Wang MM, Mortensen RM: Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke 42: 179-185, 2011
17. Takazoe K, Tesch GH, Hill PA, Hurst LA, Jun Z, Lan HY, Atkins RC, Nikolic-Paterson DJ: CD44-mediated neutrophil apoptosis in the rat. Kidney Int 58: 1920-1930, 2000
18. Kobayashi N, Hara K, Tojo A, Onozato ML, Honda T, Yoshida K, Mita S, Nakano S, Tsubokou Y, Matsuoka H: Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension 45: 538-544, 2005
19. Bienvenu LA, Morgan J, Rickard AJ, Tesch GH, Cranston GA, Fletcher EK, Delbridge LM, Young MJ: Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology 153: 3416-3425, 2012
20. Han Y, Ma FY, Tesch GH, Manthey CL, Nikolic-Paterson DJ: Role of macrophages in the fibrotic phase of rat crescentic glomerulonephritis. Am J Physiol Renal Physiol 304: F1043-F1053, 2013
21. Tsukamoto O, Minamino T, Sanada S, Okada K, Hirata A, Fujita M, Shintani Y, Yulin L, Asano Y, Takashima S, Yamasaki S, Tomoike H, Hori M, Kitakaze M: The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. Cardiovasc Drugs Ther 20: 93-102, 2006
22. Eudy RJ, Sahasrabudhe V, Sweeney K, Tugnait M, King-Ahmad A, Near K, Loria P, Banker ME, Piotrowski DW, Boustany-Kari CM: The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism. J Transl Med 9: 180, 2011
23. Chen C, Liang W, Jia J, van Goor H, Singhal PC, Ding G: Aldosterone induces apoptosis in rat podocytes: Role of PI3-K/Akt and p38MAPK signaling pathways. Nephron, Exp Nephrol 113: e26-e34, 2009
24. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T: Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 49: 355-364, 2007
25. Moeller MJ, Sanden SK, Soofi A, Wiggins RC, Holzman LB: Podocyte-specific expression of cre recombinase in transgenic mice. Genesis 35: 39-42, 2003.
26. Tesch GH, Hill PA, Wei M, Nikolic-Paterson DJ, Dutartre P, Atkins RC: LF15-0195 prevents the induction and inhibits the progression of rat anti-GBM disease. Kidney Int 60: 1354-1365, 2001
27. Takemoto M, Asker N, Gerhardt H, Lundkvist A, Johansson BR, Saito Y, Betsholtz C: A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 161: 799-805, 2002
28. Lim AK, Ma FY, Nikolic-Paterson DJ, Kitching AR, Thomas MC, Tesch GH: Lymphocytes promote albuminuria, but not renal dysfunction or histological damage in a mouse model of diabetic renal injury. Diabetologia 53: 1772-1782, 2010